Literature DB >> 23225307

Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.

Moritz Lambers1, Neil A Goldenberg, Gili Kenet, Fenella J Kirkham, Daniela Manner, Timothy Bernard, Rolf M Mesters, Ralf Junker, Monika Stoll, Ulrike Nowak-Göttl.   

Abstract

OBJECTIVE: Previous studies in adults and mice have implicated ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), also known as von Willebrand factor (VWF)-cleaving protease, as a protective factor for stroke. Here we investigated ADAMTS13 in 208 pediatric patients with arterial ischemic stroke (AIS) and 125 population-based control children in a frequency-matched case-control study.
METHODS: The proportion of patients/controls with ADAMTS13 activity levels below and above the 10th percentile was compared. Additionally, in a quintile comparison, the proportion of patients versus controls in the lowest ADAMTS13 quintile was compared to those in the 2nd to 5th quintiles. Adjustment was performed for VWF antigen (VWF:Ag), factor VIII activity (FVIII:C), blood group, and age.
RESULTS: Forty-six of 208 patients (22%) showed ADAMTS13 levels below the 10th percentile, compared with 5 of 125 controls (4%; p < 0.001). Odds ratios/95% confidence intervals were 7.30/2.73-19.50 for the lowest percentile and 2.44/1.15-5.16 in the quintile comparison after adjustment for VWF:Ag, FVIII:C, blood group, and age. Comparing the proportion of patients with ADAMTS13 activity below the 10th percentile within the different stroke subtypes (undetermined, cardioembolic, steno-occlusive arteriopathies), no statistically significant differences were found (undetermined, 16 of 89; cardioembolic, 6 of 40; steno-occlusive arteriopathies, 24 of 79; p = 0.08). ADAMTS13 levels did not significantly differ among stroke subtypes (p = 0.29).
INTERPRETATION: Our findings implicate reduced ADAMTS13 activity as a risk factor for pediatric AIS, and support the concept that ADAMTS13 has a role in the pathogenesis of pediatric AIS.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23225307      PMCID: PMC3703929          DOI: 10.1002/ana.23735

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  38 in total

Review 1.  Arterial ischaemic stroke in children. Review of the literature and strategies for future stroke studies.

Authors:  Fenella Kirkham; Guillaume Sébire; Maja Steinlin; Ronald Sträter
Journal:  Thromb Haemost       Date:  2004-10       Impact factor: 5.249

Review 2.  Paediatric stroke: genetic insights into disease mechanisms and treatment targets.

Authors:  Pinki Munot; Yanick J Crow; Vijeya Ganesan
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

3.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

4.  A proposed classification for subtypes of arterial ischaemic stroke in children.

Authors:  E Wraige; K R E Pohl; V Ganesan
Journal:  Dev Med Child Neurol       Date:  2005-04       Impact factor: 5.449

5.  Stroke in children: the coexistence of multiple risk factors predicts poor outcome.

Authors:  S Lanthier; L Carmant; M David; A Larbrisseau; G de Veber
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

Review 6.  Thrombophilia and first arterial ischaemic stroke: a systematic review.

Authors:  S Haywood; R Liesner; S Pindora; V Ganesan
Journal:  Arch Dis Child       Date:  2005-04       Impact factor: 3.791

7.  Subtypes of ischemic stroke in children and young adults.

Authors:  L S Williams; B P Garg; M Cohen; J D Fleck; J Biller
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

8.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

9.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

10.  Prospective assessment of risk factors for recurrent stroke during childhood--a 5-year follow-up study.

Authors:  Ronald Sträter; Sabine Becker; Arnold von Eckardstein; Achim Heinecke; Sven Gutsche; Ralf Junker; Karin Kurnik; Rosemarie Schobess; Ulrike Nowak-Göttl
Journal:  Lancet       Date:  2002-11-16       Impact factor: 79.321

View more
  14 in total

1.  Von Willebrand Factor: Multimeric Structure and Functional Activity in Patients With Atrial Fibrillation With and Without Oral Anticoagulation.

Authors:  Sandra Lopez-Castaneda; Ignacio Valencia-Hernández; Carlos Arean; Daniel Godínez-Hernández; Martha Eva Viveros-Sandoval
Journal:  Clin Appl Thromb Hemost       Date:  2017-06-15       Impact factor: 2.389

2.  Role of CD40 and ADAMTS13 in von Willebrand factor-mediated endothelial cell-platelet-monocyte interaction.

Authors:  Miruna Popa; Sibgha Tahir; Julia Elrod; Su Hwan Kim; Florian Leuschner; Thorsten Kessler; Peter Bugert; Ulrich Pohl; Andreas H Wagner; Markus Hecker
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-23       Impact factor: 11.205

Review 3.  von Willebrand factor, Jedi knight of the bloodstream.

Authors:  Timothy A Springer
Journal:  Blood       Date:  2014-06-13       Impact factor: 22.113

4.  von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome.

Authors:  Alice Taylor; Chiara Vendramin; Deepak Singh; Martin M Brown; Marie Scully
Journal:  Blood Adv       Date:  2020-01-28

5.  Association of Thrombin Generation With Leukocyte Inflammatory Profile in Patients With Acute Ischemic Stroke.

Authors:  Sarina Falcione; Danielle Munsterman; Twinkle Joy; Joseph Kamtchum-Tatuene; Gina Sykes; Glen Jickling
Journal:  Neurology       Date:  2022-07-05       Impact factor: 11.800

6.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

7.  Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease.

Authors:  Frederik Denorme; Peter Kraft; Inge Pareyn; Christiane Drechsler; Hans Deckmyn; Karen Vanhoorelbeke; Christoph Kleinschnitz; Simon F De Meyer
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

8.  Short-term remote ischemic conditioning may protect monkeys after ischemic stroke.

Authors:  Linlin Guo; Da Zhou; Di Wu; Jiayue Ding; Xiaoduo He; Jingfei Shi; Yunxia Duan; Tingting Yang; Yuchuan Ding; Xunming Ji; Ran Meng
Journal:  Ann Clin Transl Neurol       Date:  2019-01-15       Impact factor: 4.511

9.  A Single Synonymous Variant (c.354G>A [p.P118P]) in ADAMTS13 Confers Enhanced Specific Activity.

Authors:  Ryan Hunt; Gaya Hettiarachchi; Upendra Katneni; Nancy Hernandez; David Holcomb; Jacob Kames; Redab Alnifaidy; Brian Lin; Nobuko Hamasaki-Katagiri; Aaron Wesley; Tal Kafri; Christina Morris; Laura Bouché; Maria Panico; Tal Schiller; Juan Ibla; Haim Bar; Amra Ismail; Howard Morris; Anton Komar; Chava Kimchi-Sarfaty
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

10.  Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients.

Authors:  Consuelo M López De Padilla; Molly S Hein; Cynthia S Crowson; Christopher S Choo; Abigail B Green; Michelle Petri; Hatice Bilgic; Emily C Baechler; Ann M Reed
Journal:  SAGE Open Med       Date:  2013-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.